RxDoctor Payments Data

Todd Aaron, MD

Internal Medicine · Philadelphia, PANPI 1457350522

Payments from drug & device makers

$50in general payments, 2019–2025

Across 4 payments — averaging $12.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$25
  • Acorda Therapeutics, Inc$12
  • Johnson & Johnson$12

What the payments were for

  • Speaking & faculty fees$1225%
  • Food & beverage$3875%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$50 in reported general payments places this provider in the 30th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$455,009
Medicare patients
487
Services billed
4,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban679$231,439
IngrezzaValbenazine Tosylate17$106,663
AustedoDeutetrabenazine22$100,473
XareltoRivaroxaban244$90,530
JanuviaSitagliptin Phosphate115$48,115
Invega SustennaPaliperidone Palmitate12$29,348
TrulicityDulaglutide25$24,733
LinzessLinaclotide42$23,958
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$22,723
Atorvastatin Calcium1,174$19,549
Divalproex Sodium372$18,699
OzempicSemaglutide17$17,860
JardianceEmpagliflozin51$16,686
Incruse ElliptaUmeclidinium Bromide43$15,820
NuedextaDextromethorphan Hbr/Quinidine31$15,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invega Sustenna$12$119,878256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →